Trials / Terminated
TerminatedNCT01942083
A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, open label, non randomized, multicenter study designed to investigate the safety and tolerability of escalating doses of OPB-111077 administered orally, once daily in subjects with advanced HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPB-111077 |
Timeline
- Start date
- 2013-05-29
- Primary completion
- 2016-06-01
- Completion
- 2016-07-11
- First posted
- 2013-09-13
- Last updated
- 2017-05-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01942083. Inclusion in this directory is not an endorsement.